調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021

肺疾患・呼吸器疾患ドラックデリバリー（薬物送達）の世界市場予測（～2021年）

◆タイトル：Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021
◆商品コード：MAM-MD-5021
◆調査・発行会社：MarketsandMarkets
◆発行日：2017年2月20日
◆ページ数：153
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療機器
◆販売価格オプション（消費税別）

Single User（1名利用）	USD5,650 ⇒換算￥615,850	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥724,850	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥888,350	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、肺疾患・呼吸器疾患ドラックデリバリー（薬物送達）の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、種類別分析、デバイス別分析、需要先別分析、地域別分析、肺疾患・呼吸器疾患ドラックデリバリー（薬物送達）の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global pulmonary drug delivery market is projected to reach USD 52.37 billion by 2021 from USD 36.10 billion in 2016, at a CAGR of 6.5% during the forecast period. Increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and increasing incidence of respiratory diseases such as COPD, asthma, and cystic fibrosis is expected to drive the market growth during the forecast period. However, emerging markets and growth in online marketing channel offers opportunities for the market.
The pulmonary drug delivery market is segmented based on formulations, canister type, applications, end users, and regions.
Based on canister type, the market is segmented into plain canister and coated canister. The coated canister segment is expected to witness the highest growth during the forecast period due to various advantages such as robust profile for filling, avoiding crimping, and withstanding the pressure associated with the type of propellant (HFAs or CFCs), minimizing formulation and canister interactions and avoids deposition of HFA on the canister surface.

Based on applications, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other applications (cardiovascular disease, diabetes, respiratory therapy, and treatment of patients on ventilators). The asthma segment is expected to witness the highest growth during the forecast period due to increasing prevalence of asthma across the globe.

Based on the end user, the market is segmented into hospitals & clinics and homecare settings. Homecare settings is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to technological advancements in pulmonary drug delivery devices that enable their use in the home care settings. Digital inhalers allow patients to maintain medical records and dosage of the drug administered; this also enable patients to share this record with physicians.

Asian market is expected to register the highest CAGR during the forecast period due to the rapidly growing aging population, increasing adoption of an unhealthy lifestyle, increasing urbanization, exposure to smoke & chemicals, and the subsequent increase in the prevalence of COPD in the region. Presently, North America is expected to dominate the market. This is due to increasing technological developments, increasing prevalence of chronic respiratory and supportive reimbursement policies in the form of Medicare and Medicaid

The key players in the pulmonary drug delivery market focus on various organic and inorganic growth strategies such as agreements, collaborations, expansions, product launches & approvals, and partnerships.

The key players in this market are Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).
Apart from the comprehensive geographical analysis, product analysis, and market sizing the report also provides a competitive landscape that covers the growth strategies adopted by industry players in the last three years. In addition, the company profiles comprise basic views on the key players and their product portfolios, developments, and strategies adopted. The abovementioned market research data, current market sizes, and forecast of future trends will help key players and new entrants make informed decisions regarding product offerings, geographical focus, change in strategic approach, and R&D investments for innovations in products and technologies, and levels of output to remain successful.

Research Coverage:
The report defines, describes, and forecasts the pulmonary drug delivery market on the basis of formulations, canister type, application, end user, and regions. It provides detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, challenges). The study tracks and analyzes competitive developments such as acquisitions, product developments, and expansions in the pulmonary drug delivery market across four main regions, namely, North America, Asia, Europe, and the Rest of the World (RoW).

Reasons to buy the report:
The report on “Pulmonary Drug Delivery” provides quantitative information for clients seeking market size information on various segments of the pulmonary drug delivery market.

This report also provides access to the quantitative data on pulmonary drug delivery market. This report covers –
• Current and forecast assessment of the global pulmonary drug delivery market
• Country-wise assessment of each of the segments
• Global market share analysis of major segments of the pulmonary drug delivery market
• Adoption trends of pulmonary drug delivery in major geographic segments
• Five-year coverage of strategic developments of top players in the pulmonary drug delivery market
• Product portfolio mapping of leading players in the pulmonary drug delivery market
`

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 MARKET SCOPE 14
1.3.1 MARKETS COVERED 14
1.3.2 YEARS CONSIDERED FOR THE STUDY 14
1.4 CURRENCY 15
1.5 LIMITATIONS 15
1.6 MARKET STAKEHOLDERS 15

2 RESEARCH METHODOLOGY 16
2.1 MARKET SIZE ESTIMATION 18
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 20
2.3 KEY DATA FROM SECONDARY SOURCES 21
2.4 KEY DATA FROM PRIMARY SOURCES 21
2.5 ASSUMPTIONS FOR THE STUDY 22

3 EXECUTIVE SUMMARY 23

4 PREMIUM INSIGHTS 27
4.1 PULMONARY DRUG DELIVERY: MARKET OVERVIEW 27
4.2 GEOGRAPHIC ANALYSIS: PULMONARY DRUG DELIVERY MARKET,
BY APPLICATION (2016) 28
4.3 PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE (2016 VS. 2021) 29
4.4 PULMONARY NEBULIZERS MARKET, BY TYPE (2016–2021) 29
4.5 GEOGRAPHIC SNAPSHOT: PULMONARY DRUG DELIVERY MARKET 30

5 MARKET OVERVIEW 31
5.1 INTRODUCTION 32
5.2 MARKET DYNAMICS 32
5.2.1 MARKET DRIVERS 33
5.2.1.1 Increasing preference for pulmonary drug delivery as an alternate route of drug delivery 33
5.2.1.2 Increasing focus on the development of smart/digital inhalers 33
5.2.1.3 Increasing incidence of respiratory diseases 34
5.2.2 MARKET RESTRAINTS 35
5.2.2.1 Regulatory issues 35
5.2.2.2 Pricing pressure 35

5.2.3 MARKET OPPORTUNITIES 35
5.2.3.1 Emerging markets 35
5.2.3.2 Growth in online marketing channels 36
5.2.4 MARKET CHALLENGES 36
5.2.4.1 Issues with the stability of drugs 36
5.2.4.2 Deposition of aerosolized particles 36

6 PULMONARY DRUG DELIVERY MARKET, BY FORMULATION 37
6.1 INTRODUCTION 38
6.2 TYPE 38
6.2.1 SUSPENSION AEROSOLS 39
6.2.2 SOLUTION AEROSOLS 40
6.2.3 DRY POWDER FORMULATIONS 41
6.3 DEVICE TYPE 42
6.3.1 METERED DOSE INHALERS (MDIS) 43
6.3.2 DRY POWDER INHALERS (DPIS) 44
6.3.3 NEBULIZERS 45
6.3.3.1 Jet Nebulizers 46
6.3.3.2 Ultrasonic Nebulizers 47
6.3.3.3 Soft mist nebulizers 48

7 PULMONARY DRUG DELIVERY MARKET, BY CANISTER TYPE 49
7.1 INTRODUCTION 50
7.2 PLAIN CANISTERS 50
7.3 COATED CANISTER 51

8 PULMONARY DRUG DELIVERY MARKET, BY APPLICATION 52
8.1 INTRODUCTION 53
8.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 54
8.3 ASTHMA 55
8.4 CYSTIC FIBROSIS 56
8.5 OTHER APPLICATIONS 57

9 PULMONARY DRUG DELIVERY MARKET, BY END USER 58
9.1 INTRODUCTION 59
9.2 HOSPITALS & CLINICS 60
9.3 HOME CARE SETTINGS 61

10 PULMONARY DRUG DELIVERY MARKET, BY REGION 62
10.1 INTRODUCTION 63
10.2 NORTH AMERICA 64
10.2.1 U.S. 69
10.2.2 CANADA 72
10.3 EUROPE 75
10.3.1 GERMANY 80
10.3.2 U.K. 83
10.3.3 FRANCE 86
10.3.4 REST OF EUROPE 89
10.4 ASIA 92
10.4.1 CHINA 97
10.4.2 INDIA 100
10.4.3 JAPAN 103
10.4.4 REST OF ASIA 106
10.5 REST OF THE WORLD 109

11 COMPETITIVE LANDSCAPE 112
11.1 OVERVIEW 112
11.2 MARKET RANK ANALYSIS 113
11.3 COMPETITIVE SITUATIONS AND TRENDS 114
11.3.1 COLLABORATIONS 115
11.3.2 PRODUCT LAUNCHES AND REGULATORY APPROVALS 116
11.3.3 ACQUISITIONS 117
11.3.4 EXPANSIONS 117

12 COMPANY PROFILES 118
(Overview, Products and Services, Financials, Strategy & Development)*
12.1 INTRODUCTION 118
12.2 TEVA PHARMACEUTICAL INDUSTRIES LTD. 119
12.3 3M 121
12.4 GLAXOSMITHKLINE PLC 123
12.5 ASTRAZENECA PLC 125
12.6 BOEHRINGER INGELHEIM 128
12.7 MERCK & CO., INC. 130
12.8 NOVARTIS AG 132
12.9 OMRON CORPORATION 134

12.10 SUNOVION PHARMACEUTICALS INC. (A PART OF SUMITOMO DAINIPPON PHARMA CO., LTD.) 136
12.11 CIPLA INC. 138
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13 APPENDIX 140
13.1 INSIGHTS FROM INDUSTRY EXPERTS 140
13.2 DISCUSSION GUIDE 141
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 145
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 147
13.5 AVAILABLE CUSTOMIZATIONS 148
13.6 RELATED REPORTS 149
13.7 AUTHOR DETAILS 150

LIST OF TABLES

TABLE 1 COMPANIES DEVELOPING SMART/DIGITAL INHALER TECHNOLOGIES 33
TABLE 2 PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE,
2014–2021 (USD MILLION) 38
TABLE 3 SUSPENSION AEROSOLS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 39
TABLE 4 SOLUTION AEROSOLS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 40
TABLE 5 DRY POWDER FORMULATIONS MARKET SIZE, BY REGION,
2014–2021 (USD MILLION) 41
TABLE 6 PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE , 2014–2021 (USD MILLION) 42
TABLE 7 METERED DOSE INHALERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 43
TABLE 8 DRY DOSE INHALERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 44
TABLE 9 NEBULIZERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 45
TABLE 10 NEBULIZERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 45
TABLE 11 JET NEBULIZERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 46
TABLE 12 ULTRASONIC NEBULIZERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 47
TABLE 13 SOFT MIST NEBULIZERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 48
TABLE 14 PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 50
TABLE 15 PLAIN CANISTERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 50
TABLE 16 COATED CANISTERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 51
TABLE 17 PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 53
TABLE 18 PULMONARY DRUG DELIVERY MARKET SIZE FOR COPD, BY REGION,
2014–2021 (USD MILLION) 54
TABLE 19 PULMONARY DRUG DELIVERY MARKET SIZE FOR ASTHMA, BY REGION,
2014–2021 (USD MILLION) 55
TABLE 20 PULMONARY DRUG DELIVERY MARKET SIZE FOR CYSTIC FIBROSIS, BY REGION, 2014–2021 (USD MILLION) 56
TABLE 21 PULMONARY DRUG DELIVERY MARKET SIZE FOR OTHER APPLICATIONS,
BY REGION, 2014–2021 (USD MILLION) 57
TABLE 22 PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 59
TABLE 23 PULMONARY DRUG DELIVERY MARKET SIZE FOR HOSPITALS & CLINICS,
BY REGION, 2014–2021 (USD MILLION) 60
TABLE 24 PULMONARY DRUG DELIVERY MARKET SIZE FOR HOME CARE SETTINGS,
BY REGION, 2014–2021 (USD MILLION) 61
TABLE 25 GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY REGION,
2014–2021 (USD MILLION) 63
TABLE 26 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 66
TABLE 27 NORTH AMERICA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY TYPE, 2014–2021 (USD MILLION) 66
TABLE 28 NORTH AMERICA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 67
TABLE 29 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION) 67
TABLE 30 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 68
TABLE 31 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION) 68
TABLE 32 U.S.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 69
TABLE 33 U.S.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 70
TABLE 34 U.S.: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 70
TABLE 35 U.S.: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 71
TABLE 36 U.S.: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 71
TABLE 37 CANADA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 72
TABLE 38 CANADA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 73
TABLE 39 CANADA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 73
TABLE 40 CANADA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 74
TABLE 41 CANADA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 74
TABLE 42 EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 77
TABLE 43 EUROPE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 77
TABLE 44 EUROPE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 78
TABLE 45 EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 78
TABLE 46 EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 79
TABLE 47 EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 79
TABLE 48 GERMANY: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 80
TABLE 49 GERMANY: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 81
TABLE 50 GERMANY: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION) 81
TABLE 51 GERMANY: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 82
TABLE 52 GERMANY: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 82
TABLE 53 U.K.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 83
TABLE 54 U.K.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 84
TABLE 55 U.K.: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 84
TABLE 56 U.K.: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 85
TABLE 57 U.K.: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 85
TABLE 58 FRANCE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 86
TABLE 59 FRANCE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 87
TABLE 60 FRANCE: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 87
TABLE 61 FRANCE: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 88
TABLE 62 FRANCE: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 88
TABLE 63 ROE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 89
TABLE 64 ROE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 90
TABLE 65 ROE: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 90
TABLE 66 ROE: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 91
TABLE 67 ROE: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 91
TABLE 68 ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 94
TABLE 69 ASIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 94
TABLE 70 ASIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 95
TABLE 71 ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 95
TABLE 72 ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 96
TABLE 73 ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 96
TABLE 74 CHINA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 97
TABLE 75 CHINA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 98
TABLE 76 CHINA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 98
TABLE 77 CHINA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 99
TABLE 78 CHINA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 99
TABLE 79 INDIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 100
TABLE 80 INDIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 101
TABLE 81 INDIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 101
TABLE 82 INDIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 102
TABLE 83 INDIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 102
TABLE 84 JAPAN: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 103
TABLE 85 JAPAN: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 104
TABLE 86 JAPAN: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 104
TABLE 87 JAPAN: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 105
TABLE 88 JAPAN: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 105
TABLE 89 ROA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 106
TABLE 90 ROA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 107
TABLE 91 ROA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 107
TABLE 92 ROA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 108
TABLE 93 ROA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 108
TABLE 94 ROW: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 109
TABLE 95 ROW: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,
BY DEVICE TYPE, 2014–2021 (USD MILLION) 110
TABLE 96 ROW: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2014–2021 (USD MILLION) 110
TABLE 97 ROW: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 111
TABLE 98 ROW: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2014–2021 (USD MILLION) 111
TABLE 99 MARKET RANKING OF THE KEY PLAYERS IN THE PULMONARY DRUG DELIVERY MARKET (2015) 113
TABLE 100 COLLABORATIONS, 2014–2016 115
TABLE 101 PRODUCT LAUNCHES AND REGULATORY APPROVALS, 2014–2016 116
TABLE 102 ACQUISITIONS, 2014–2016 117
TABLE 103 EXPANSIONS, 2014–2016 117
TABLE 104 EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF GBP TO USD) 123

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 16
FIGURE 2 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 18
FIGURE 3 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 19
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 19
FIGURE 5 DATA TRIANGULATION METHODOLOGY 20
FIGURE 6 GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE,
2016 VS. 2021 23
FIGURE 7 GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION,
2016 VS. 2021 24
FIGURE 8 GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE,
2016 VS. 2021 24
FIGURE 9 GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,
2016 VS. 2021 25
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE PULMONARY DRUG DELIVERY MARKET 26
FIGURE 11 INCREASING INCIDENCE OF RESPIRATORY DISEASES IS A KEY MARKET DRIVER FOR PULMONARY DRUG DELIVERY 27
FIGURE 12 ASTHMA FORMS THE LARGEST APPLICATION SEGMENT IN THE PULMONARY DRUG DELIVERY MARKET 28
FIGURE 13 METERED-DOSE INHALERS TO COMMAND THE LARGEST MARKET SHARE IN 2016 29
FIGURE 14 JET NEBULIZERS TO DOMINATE THE PULMONARY NEBULIZERS MARKET IN 2016 29
FIGURE 15 CHINA TO REGISTER HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 30
FIGURE 16 PULMONARY DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 32
FIGURE 17 U.K.: ESTIMATED NUMBER OF PEOPLE DIAGNOSED WITH ASTHMA (2004–2012) 34
FIGURE 18 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SNAPSHOT 65
FIGURE 19 EUROPE: PULMONARY DRUG DELIVERY MARKET SNAPSHOT 76
FIGURE 20 ASIA: PULMONARY DRUG DELIVERY MARKET SNAPSHOT 93
FIGURE 21 KEY DEVELOPMENTS IN THE PULMONARY DRUG DELIVERY MARKET, 2014–2016 112
FIGURE 22 BATTLE FOR MARKET SHARE: COLLABORATIONS ACCOUNTED FOR THE LARGEST SHARE OF THE TOTAL DEVELOPMENTS DURING 2014 TO 2016 114
FIGURE 23 GEOGRAPHIC REVENUE MIX FOR THE TOP 5 PLAYERS IN THE PULMONARY DRUG DELIVERY MARKET 118
FIGURE 24 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2015) 119
FIGURE 25 3M: COMPANY SNAPSHOT (2015) 121
FIGURE 26 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2015) 123
FIGURE 27 ASTRAZENECA PLC: COMPANY SNAPSHOT (2015) 125
FIGURE 28 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2015) 128
FIGURE 29 MERCK & CO., INC.: COMPANY SNAPSHOT (2015) 130
FIGURE 30 NOVARTIS AG: COMPANY SNAPSHOT (2015) 132
FIGURE 31 OMRON CORPORATION: COMPANY SNAPSHOT (2015) 134
FIGURE 32 SUMITOMO DAINIPPON PHARMA CO., LTD.: COMPANY SNAPSHOT (2015) 136
FIGURE 33 CIPLA INC.: COMPANY SNAPSHOT (2016) 138

【レポートのキーワード】

肺疾患ドラックデリバリー、肺疾患治療薬、医薬品、呼吸器疾患ドラックデリバリー、薬物送達、呼吸器疾患治療薬

★調査レポート[肺疾患・呼吸器疾患ドラックデリバリー（薬物送達）の世界市場予測（～2021年）] ( Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021 / MAM-MD-5021) 販売に関する免責事項

[肺疾患・呼吸器疾患ドラックデリバリー（薬物送達）の世界市場予測（～2021年）] ( Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021 / MAM-MD-5021) についてEメールでお問い合わせ

◆関連調査資料◆

外来用生涯電子カルテ（EHR）の世界市場予測（～2021年）
MAM-HIT5227 / MarketsandMarkets / 2017年5月3日 / 当調査レポートでは、外来用生涯電子カルテ（EHR）の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、提供方式別分析、用途別分析、需要先別分析、地域別分析、外来用生涯電子カルテ（EHR）の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global ambulatory EHR market is expected to reach USD 5.20 billion by 2021 from USD 3.92 billion in 2016, at a CAGR of 5.8%. The major drivers for the market include government support for the adoption of HCIT, growing usage of EHR solutions, and the need to curtail the healthcare costs. On the other hand, heavy infrastructure investments and the high cost of deployment are limiting the growth of the global ambulatory EHR market to a certain extent. The market is segmented on the basis of application, delivery mode, practice size, end user, and region. The application segment includes...

金属バイオサイド（殺生物剤）の世界市場予測（～2021年）:銀、銅&銅合金、亜鉛
MAM-CH4885 / MarketsandMarkets / 2017年1月10日 / MarketsandMarketsが発行した当調査レポートでは、金属バイオサイド（殺生物剤）の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、バリューチェーン分析、市場環境分析、種類別分析、需要先別分析、地域別分析、金属バイオサイド（殺生物剤）の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global metal biocides market is projected to reach USD 3.49 Billion by 2021 at a CAGR of 4.8% from 2016 to 2021. The market is primarily driven by the rapid growth of the key end-use industries, such as paints & coatings, medical, and textile. Metal biocides are used in end-use industries such as, paints & coatings, medical, textile, pesticides (agriculture), wood preservation, foods & beverages, and others. In 2015, the medical sector accounted for the largest market share among the end-use industries, in terms of value. Whereas, the paints & coatings segment is expected to register the highest CAGR,...

セルソーティング（細胞選別）の世界市場予測（～2021年）：セルソーター、試薬、消耗品
MAM-BT4864 / MarketsandMarkets / 2017年1月6日 / MarketsandMarketsが発行した当調査レポートでは、セルソーティング（細胞選別）の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、バリューチェーン分析、市場シェア分析、市場環境分析、技術別分析、製品別分析、用途別分析、需要先別分析、セルソーティング（細胞選別）の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The cell sorting market is expected to reach USD 247.4 Million by 2021 from USD 176.5 Million in 2016, at a CAGR of 7.0% between 2016 and 2021. Factors such as technological advancements in cell sorters, rising funding and investments for development of innovative cell sorting techniques, growing adoption of cell sorter techniques in research activities, and launch of specific reagents for specific applications are driving the growth of this market. However, factors such as the lack of awareness and technical knowledge regarding the use of cell sorters and high cost of instruments are hampering the growth of this market....

高力価API（医薬品原薬）の世界市場予測（～2021年）
MAM-PH4897 / MarketsandMarkets / 2017年1月12日 / MarketsandMarketsが発行した当調査レポートでは、高力価API（医薬品原薬）の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、種類別分析、合成別分析、製造企業別分析、地域別分析、高力価API（医薬品原薬）の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global active pharmaceutical ingredients market is expected to reach USD 24.09 Billion by 2021 from USD 16.02 Billion in 2016, growing at a CAGR of 8.5% from 2016 to 2021. Market growth is driven by the rapid growth in the oncology drugs market, growing demand for antibody drug conjugates, increasing focus of pharmaceutical companies on HPAPIs, and advancements in HPAPI technologies. Furthermore emerging markets and emerging technologies have opened an array of opportunities for the growth of the high potency active pharmaceutical ingredients market. The market also offers lucrative growth opportunities for CMO and CDMOs. However, factors such as...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆